Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | GUSB | P08236 | 2/20 | 0.36 |
| ▸ | GBA1 | P04062 | 4/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.30 |
| ▸ | HRH1 | P35367 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542804 | 0.87 | HRH3 (0.46) | HRH3HTR1AHRH2HRH1 | |
| SCHEMBL13543540 | 0.87 | HRH3 (0.46) | HRH3HTR1AHRH2HRH1 | |
| SCHEMBL22861398 | 0.85 | HTR1A (0.51) | HRH3HTR1AHRH2HRH1 | |
| SCHEMBL22890922 | 0.85 | HTR1A (0.51) | HRH3HTR1AHRH2HRH1 | |
| SCHEMBL20739182 | 0.84 | HRH3 (0.39) | GLB1HRH3GUSBGBA1SIGMAR1 | |
| SCHEMBL22890929 | 0.83 | HRH3 (0.41) | HRH3SIGMAR1HRH2HRH1 | |
| SCHEMBL23373644 | 0.80 | HRH3 (0.36) | HRH3HRH2HRH1 | |
| SCHEMBL22861467 | 0.80 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL22861478 | 0.80 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL13543410 | 0.77 | MEN1 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568874-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190282555-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282555-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | GLB1 3043/4885HRH3 11/4885GUSB 4610/4885 |
| US-10568874-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | GLB1 3043/4885HRH3 11/4885GUSB 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.